1 / 42

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients. Program Goals. The Incretin System: Response to Oral Glucose. Injected Incretin-based Agents: GLP-1 Receptor Agonists. Oral Incretin-based Agents: DPP-4 Inhibitors .

roza
Download Presentation

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients

  2. Program Goals

  3. The Incretin System: Response to Oral Glucose

  4. Injected Incretin-based Agents: GLP-1 Receptor Agonists

  5. Oral Incretin-based Agents: DPP-4 Inhibitors

  6. Main Pathophysiological Defects in T2D

  7. T2D Anti-Hyperglycemic Therapy: General Recommendations

  8. Approaches to Intensifying Therapy in Patients Not At Goal on Basal Insulin

  9. Adding Prandial Insulin to Basal Insulin: Key Challenges

  10. Scientific Rationale for Combining Basal Insulin with a GLP-1 agonist

  11. DPP- 4 Inhibitors as Add-ons to Basal Insulin

  12. Pramlintide as Add-on to Basal Insulin

  13. Twice-daily Exenatide as Add-on to Basal Insulin (Glargine)

  14. Twice-daily Exenatide as Add-on to Basal Insulin (Glargine): Results

  15. Metformin plus Liraglutide Followed by Add-on of Basal Insulin (Detemir)

  16. Metformin plus Liraglutide Followed by Add-on of Basal Insulin (Detemir)

  17. Oral Agents Plus Basal Insulin (Glargine) Followed by Add-on Lixisenatide*

  18. Oral Agents Plus Basal Insulin (Glargine) Followed by Add-on Lixisenatide* (cont)

  19. Other Safety Concerns With GLP-1 Receptor Agonists

  20. Lixisenatide* vs Liraglutide: Effect on Postprandial Glucose Levels†

  21. Comparison of Basal Insulin + Lixisenatide* and Basal-Plus Regimensa

  22. IDegLira* vs Degludec* or Liraglutide Alone: Effect on HbA1c

  23. IDegLira* vs Degludec* or Liraglutide Alone: Results

  24. Abbreviations

  25. Abbreviations (cont)

  26. References

  27. References (cont)

  28. References (cont)

  29. References (cont)

  30. References (cont)

  31. References (cont)

  32. References (cont)

  33. References (cont)

  34. References (cont)

  35. References (cont)

  36. References (cont)

  37. References (cont)

More Related